A critical review on the role of nanotheranostics mediated approaches for targeting β amyloid in Alzheimer's
Alzheimer's is one of the most common neurodegenerative illnesses that affect brain cellular function. In this disease, the neurons in the brain are considered to be decaying steadily but consistently by the accumulation of amyloid mass, particularly the β-amyloids, amyloid proteins, and Tau proteins. The most responsible amyloid-proteins are amyloid-40 and amyloid-42, which have a high probability of accumulating in excess over the brain cell, interfering with normal brain cell function and triggering brain cell death. The advancement of pharmaceutical sciences leads to the development of Nanotheranostics technology, which may be used to diagnose and treat Alzheimer's. They are the colloidal nanoparticles functionalised with the therapeutic moiety as well as a diagnostic moiety. This article discusses the prognosis of Alzheimer's, various nanotheranostics approaches (nanoparticles, quantum dots, aptamers, dendrimers, etc), and their recent advancement in managing Alzheimer's. Also, various in-vitro and in-vivo diagnostic methodologies were discussed with respect to nanotheranostics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Journal of drug targeting - 31(2023), 7 vom: 08. Aug., Seite 725-744 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rastogi, Vaibhav [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alzheimer’s |
|---|
| Anmerkungen: |
Date Completed 31.07.2023 Date Revised 31.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/1061186X.2023.2238250 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359602835 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359602835 | ||
| 003 | DE-627 | ||
| 005 | 20231226081229.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/1061186X.2023.2238250 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1198.xml |
| 035 | |a (DE-627)NLM359602835 | ||
| 035 | |a (NLM)37459647 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rastogi, Vaibhav |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A critical review on the role of nanotheranostics mediated approaches for targeting β amyloid in Alzheimer's |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.07.2023 | ||
| 500 | |a Date Revised 31.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Alzheimer's is one of the most common neurodegenerative illnesses that affect brain cellular function. In this disease, the neurons in the brain are considered to be decaying steadily but consistently by the accumulation of amyloid mass, particularly the β-amyloids, amyloid proteins, and Tau proteins. The most responsible amyloid-proteins are amyloid-40 and amyloid-42, which have a high probability of accumulating in excess over the brain cell, interfering with normal brain cell function and triggering brain cell death. The advancement of pharmaceutical sciences leads to the development of Nanotheranostics technology, which may be used to diagnose and treat Alzheimer's. They are the colloidal nanoparticles functionalised with the therapeutic moiety as well as a diagnostic moiety. This article discusses the prognosis of Alzheimer's, various nanotheranostics approaches (nanoparticles, quantum dots, aptamers, dendrimers, etc), and their recent advancement in managing Alzheimer's. Also, various in-vitro and in-vivo diagnostic methodologies were discussed with respect to nanotheranostics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Alzheimer’s | |
| 650 | 4 | |a aptamers | |
| 650 | 4 | |a dendrimers | |
| 650 | 4 | |a nanoparticles | |
| 650 | 4 | |a nanotheranostics | |
| 650 | 4 | |a quantum dots | |
| 650 | 7 | |a Amyloid beta-Peptides |2 NLM | |
| 650 | 7 | |a tau Proteins |2 NLM | |
| 650 | 7 | |a Amyloid |2 NLM | |
| 700 | 1 | |a Jain, Anjali |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Prashant |e verfasserin |4 aut | |
| 700 | 1 | |a Yadav, Pragya |e verfasserin |4 aut | |
| 700 | 1 | |a Porwal, Mayur |e verfasserin |4 aut | |
| 700 | 1 | |a Chaturvedi, Shashank |e verfasserin |4 aut | |
| 700 | 1 | |a Chandra, Phool |e verfasserin |4 aut | |
| 700 | 1 | |a Verma, Anurag |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of drug targeting |d 1996 |g 31(2023), 7 vom: 08. Aug., Seite 725-744 |w (DE-627)NLM074733958 |x 1029-2330 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2023 |g number:7 |g day:08 |g month:08 |g pages:725-744 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/1061186X.2023.2238250 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2023 |e 7 |b 08 |c 08 |h 725-744 | ||